Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.45 |
| ▸ | DHODH | Q02127 | 7/20 | 0.45 |
| ▸ | LDHA | P00338 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | KDM4A | O75164 | 1/20 | 0.39 |
| ▸ | KDM5A | P29375 | 1/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | KMO | O15229 | 1/20 | 0.39 |
| ▸ | PTGES | O14684 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6772451 | 0.89 | LMNA (0.42) | SMN1; SMN2LMNAFOLH1DHODHPTGES | |
| SCHEMBL4518271 | 0.88 | KMO (0.49) | SMN1; SMN2LMNADHODHCYP3A4CYP2C8 | |
| SCHEMBL28143127 | 0.86 | CDC7 (0.46) | SMN1; SMN2LMNADHODHCYP3A4PTGES | |
| SCHEMBL4520576 | 0.85 | DHODH (0.48) | SMN1; SMN2LMNADHODHLDHAKDM4A | |
| SCHEMBL4514183 | 0.85 | DHODH (0.46) | SMN1; SMN2LMNADHODHKDM4EKDM5A | |
| SCHEMBL4523605 | 0.83 | KMO (0.51) | DHODHKDM5AKDM4CKDM5BKMO | |
| SCHEMBL25120650 | 0.81 | DHODH (0.42) | SMN1; SMN2LMNADHODHKDM4EKDM5A | |
| SCHEMBL5526122 | 0.81 | KDM5A (0.48) | SMN1; SMN2LMNADHODHLDHAKDM5A | |
| SCHEMBL30949178 | 0.81 | DHODH (0.42) | SMN1; SMN2LMNADHODHKDM4EKDM5A | |
| SCHEMBL30377825 | 0.81 | KDM5A (0.48) | SMN1; SMN2LMNADHODHLDHAKDM5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130023541-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED | 2013-01-24 | — | — | US | disclosed |
| EP-2523665-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | Glaxo Group Limited (GB) | 2012-11-21 | — | — | EP | disclosed |
| CN-101589025-B | Aminonicotinic acid and isonicotinic acid derivatives as dihydrolactate dehydrogenase (DHODH) inhibitors | ALMIRALL LAB | 2012-05-30 | — | — | CN | disclosed |
| WO-2011088201-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | GLAXO GROUP LIMITED (GB) | 2011-07-21 | — | — | WO | disclosed |
| US-7625887-B2 | Receptor agonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-01 | — | — | US | disclosed |
| CN-101589025-A | Aminonicotinic acid and isonicotinic acid derivatives as dihydrolactate dehydrogenase (DHODH) inhibitors | ALMIRALL LAB (ES) | 2009-11-25 | — | — | CN | disclosed |
| CN-100506801-C | Inhibitors of glycogen synthase kinase 3 | CHIRON CORP (US) | 2009-07-01 | — | — | CN | disclosed |
| US-20060199795-A1 | Receptor agonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-09-07 | — | — | US | disclosed |
| EP-1591120-A1 | RECEPTOR AGONISTS | Takeda Chemical Industries, Ltd. (JP) | 2005-11-02 | — | — | EP | disclosed |
| CN-1592743-A | Inhibitors of glycogen synthase kinase 3 | CHIRON CORP (US) | 2005-03-09 | — | — | CN | disclosed |
| EP-1061926-A2 | HETEROCYCLIC COMPOUNDS, THEIR PRODUCTION AND USE AS TACHYKININ RECEPTOR ANTAGONISTS | Takeda Chemical Industries, Ltd. (JP) | 2000-12-27 | — | — | EP | disclosed |
| US-6147071-A | TACHYKININ RECEPTOR ANTAGONIST | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-11-14 | — | — | US | disclosed |
| WO-1999047132-A2 | HETEROCYCLIC COMPOUNDS, THEIR PRODUCTION AND USE AS TACHYKININ RECEPTOR ANTAGONISTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-09-23 | — | — | WO | disclosed |
| US-5786352-A | CARDIOVASCULAR DISORDERS, TACHYKININ RECEPTOR ANTAGONIST | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-07-28 | — | — | US | disclosed |
| US-5770590-A | EXCELLENT TACHYKININ RECEPTOR ANTAGONIST | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-06-23 | — | — | US | disclosed |
| CN-1140172-A | Cyclic compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1997-01-15 | — | — | CN | disclosed |
| EP-0733632-A1 | Cyclic compounds, their production and use as tachykinin receptor antagonists | Takeda Chemical Industries, Ltd. (JP) | 1996-09-25 | — | — | EP | disclosed |
| US-4623648-A | 1-azaxanthone for use as therapeutic agent as an antipyretic, analgesic, anti-inflammatory and bronchodilator | LACER, S.A. (ES) | 1986-11-18 | — | — | US | disclosed |
| EP-0075607-B1 | 1-AZAXANTHONE FOR USE AS THERAPEUTIC AGENT, PROCESSES FOR ITS PRODUCTION AND PHARMACEUTICAL COMPOSITIONS | LACER, S.A. (ES) | 1985-03-13 | — | — | EP | disclosed |
| EP-0075607-A1 | 1-Azaxanthone for use as therapeutic agent, processes for its production and pharmaceutical compositions | LACER, S.A. (ES) | 1983-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023541-A1 | VOLTAGE-GATED SODIUM CHANNEL BLOCKERS | KCNB1, KCNB2, SCNN1B | SMN1; SMN2 1087/4885LMNA 611/4885FOLH1 4656/4885 |
| US-20060199795-A1 | Receptor agonists | GPBAR1, GPR35, GPR55 | SMN1; SMN2 3951/4885LMNA 3887/4885FOLH1 1153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.